IRCT20220122053792N1 IRCT 2022-03-06 Oroumia University of Medical Sciences Evaluation of the effect of Eplerenone in Central serous chorioretinopathy )CSCR Evaluation of the effect of Eplerenone in Central serous chorioretinopathy )CSCR 2022-01-15 anticipated 34 Complete https://irct.ir/trial/61462 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, patients will be randomly divided into two groups of treatment (administration of Eplerenone) and control (placebo of neutral drug) with random allocation software (Random Allocation software), Blinding description: 606 / 5,000 Translation results In the present study, patients and the treatment team (physicians) had no knowledge that each patient was in the treatment group or placebo group. Patients will be divided into two groups of treatment or placebo based on randomization after their disease is diagnosed. Then, without knowing which group each patient is in, the researcher will enter the patient in the study and the relevant treatment will be started and will be visited for follow-up in the future. Patients also do not know which group they belong to until the end of the study period. After the person is diagnosed with the disease by an ophthalmologist, participants are referred to a secretary for medication or a placebo. 1-2 Chronic central serous chorioretinopathy. Intervention 1: Intervention group:For patients in the intervention group, Eplerenone will be administered at a dose of 25 mg for one week and then at a dose of 50 mg for three weeks. Intervention 2: Control group: In the control group, placebo will be prescribed for 4 weeks. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is I will make a decision to publish after the completion of the project and according to the results